Service interruption on Monday 11 July from 12:30 to 13:00: all the sites of the CCSD (HAL, Epiciences, SciencesConf, AureHAL) will be inaccessible (network hardware connection).
Skip to Main content Skip to Navigation
Journal articles

SARS-CoV-2 T-Cell Responses in Allogeneic Hematopoietic Stem Cell Recipients following Two Doses of BNT162b2 mRNA Vaccine

Abstract : Background: At variance to humoral responses, cellular immunity after anti-SARS-CoV-2 vaccines has been poorly explored in recipients of allogeneic hematopoietic stem-cell transplantation (Allo-HSCT), especially within the first post-transplant years where immunosuppression is more profound and harmful. Methods: SARS-CoV-2 Spike protein-specific T-cell responses were explored after two doses of BNT162b2 mRNA vaccine in 45 Allo-HSCT recipients with a median time from transplant of less than 2 years by using INF-γ ELISPOT assay and flow-cytometry enumeration of CD4+ and CD8+ T lymphocytes with intracellular cytokine production of IFN-γ and TNF-α. Results: A strong TNF-α+ response from SARS-CoV-2-specific CD4+ T-cells was detected in a majority of humoral responders (89%) as well as in a consistent population of non-humoral responders (40%). Conclusions: T-cells are likely to participate in protection against COVID-19 viral infection, even in the absence of detectable antibody response, especially in the first years post-transplant in Allo- HSCT recipients.
Document type :
Journal articles
Complete list of metadata

https://www.hal.inserm.fr/inserm-03611946
Contributor : Jocelyn Ollier Connect in order to contact the contributor
Submitted on : Thursday, March 17, 2022 - 2:27:48 PM
Last modification on : Wednesday, April 27, 2022 - 4:59:53 AM
Long-term archiving on: : Saturday, June 18, 2022 - 7:18:28 PM

File

vaccines-10-00448-v3.pdf
Publisher files allowed on an open archive

Identifiers

Collections

Citation

Béatrice Clémenceau, Thierry Guillaume, Marianne Coste-Burel, Pierre Peterlin, Alice Garnier, et al.. SARS-CoV-2 T-Cell Responses in Allogeneic Hematopoietic Stem Cell Recipients following Two Doses of BNT162b2 mRNA Vaccine. Vaccines, MDPI, 2022, 10 (3), pp.448. ⟨10.3390/vaccines10030448⟩. ⟨inserm-03611946⟩

Share

Metrics

Record views

21

Files downloads

12